 Home > Biochemistry News > Biotechnology News > Innovative radiotherapy for the treatment of fatal and aggressive brain tumors was recognized as a breakthrough medical device by the FDA

Innovative radiotherapy for the treatment of fatal and aggressive brain tumors was recognized as a breakthrough medical device by the FDA

 Last Update: 2021-10-21
 Source: Internet
 Author: User

Tags

trojan horse cancer treatment

microwave radiation cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Alpha Tau Medical announced that the US FDA has granted its innovative alpha radiation cancer therapy Alpha DaRT breakthrough medical device designation for the treatment of patients with recurrent glioblastoma multiforme (GBM)
.

On June 8th of this year, Alpha DaRT was granted breakthrough medical device designation by the FDA for the first time for the treatment of skin and oral squamous cell carcinomas without curative standard therapies

GBM is an aggressive malignant brain cancer with an average 5-year survival rate of less than 10%.
It is the most common malignant tumor of the brain or central nervous system
.

Alpha DaRT will be used as an adjunct to standard drug therapy, or as an independent therapy after standard drug therapy fails, for the treatment of recurrent GBM

Alpha DaRT is treated by intratumor injection, implanting "seeds" carrying radioactive radium-224 into the tumor
.

When the unstable radioactive radium-224 fission, it will release high-energy alpha particles, thereby destroying the tumor

▲The alpha particles produced by the Alpha DaRT fission process can kill tumors (picture source: Alpha Tau Medical official website)

Reference materials:

[1] Alpha Tau Receives FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.